US 11,932,653 B2
Lycorine derivative, and pharmaceutical composition and use thereof
Xiandao Pan, Beijing (CN); Yajun Yang, Beijing (CN); Longying Shen, Beijing (JP); Wensheng Zheng, Beijing (CN); Shuwang He, Rongcheng (CN); Shiqiang Yan, Rongcheng (CN); and Yajun Jing, Rongcheng (CN)
Assigned to SHANDONG DYNE MARINE BIOPHARMACEUTICAL CO., LTD, Shandong (CN); and BEIJING DYNE HIGH-TECH PEDIATRIC PHARMACEUTICAL R&D INSTITUTE CO., LTD., Shandong (CN)
Appl. No. 17/056,533
Filed by SHANDONG DYNE MARINE BIOPHARMACEUTICAL CO., LTD, Shandong (CN); and BEIJING DYNE HIGH-TECH PEDIATRIC PHARMACEUTICAL R&D INSTITUTE CO., LTD., Beijing (CN)
PCT Filed Jul. 27, 2018, PCT No. PCT/CN2018/097678
§ 371(c)(1), (2) Date Nov. 18, 2020,
PCT Pub. No. WO2020/019357, PCT Pub. Date Jan. 30, 2020.
Prior Publication US 2021/0206777 A1, Jul. 8, 2021
Int. Cl. C07D 491/16 (2006.01); A61P 31/14 (2006.01)
CPC C07D 491/16 (2013.01) [A61P 31/14 (2018.01)] 10 Claims
 
1. A lycorine derivative of General Formula (I), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein X is O, S or CH2; n=0, 1, 2, 3, 4, or 5; Ar is a C6-10 aromatic ring or a C3-10 heteroaromatic ring; R is optionally mono-substituted, di-substituted or multi-substituted, and R is independently selected from hydrogen, halogen, nitro, amino, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C6-10 aryl, C1-6 alkynyl, C1-6 alkenyl, C3-6 cycloalkyl, C3-6 heterocycloalkyl, C1-6 alkylacyl, and C6-10 arylacyl, where the C3-10 heteroaromatic ring contains a heteroatom, and the heteroatom is selected from N, O, and S.